Abstract
Purpose
To establish and validate a multiparameter prediction model for early recurrence after radical resection in patients diagnosed with combined hepatocellular-cholangiocarcinoma (cHCC-CC).
Materials and methods
This study reviewed the clinical characteristics and preoperative CT images of 143 cHCC-CC patients who underwent radical resection from three institutions. A total of 110 patients from institution 1 were randomly divided into training set (n = 78) and testing set (n = 32) in the ratio of 7–3. Univariate and multivariate logistic regression analysis were used to construct a nomogram prediction model in the training set, which was internally and externally validated in the testing set and the validation set (n = 33) from institutions 2 and 3. The area under the curve (AUC) of receiver operating characteristics (ROC), decision curve analysis (DCA), and calibration analysis were used to evaluate the model’s performance.
Results
The combined model demonstrated superior predictive performance compared to the clinical model, the CT model, the pathological model and the clinic-CT model in predicting the early postoperative recurrence. The nomogram based on the combined model included AST, ALP, tumor size, tumor margin, arterial phase peritumoral enhancement, and MVI (Microvascular invasion). The model had AUCs of 0.89 (95% CI 0.81–0.96), 0.85 (95% CI 0.70–0.99), and 0.86 (95% CI 0.72–1.00) in the training, testing, and validation sets, respectively, indicating high predictive power. DCA showed that the combined model had good clinical value and correction effect.
Conclusion
A nomogram incorporating clinical characteristics and preoperative CT features can be utilized to effectively predict the early postoperative recurrence in patients with cHCC-CC.
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Avoid common mistakes on your manuscript.
Introduction
Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a rare primary liver carcinoma primarily consisting of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) [1]. The incidence of cHCC-CC varies from 0.4 to 14.2% across different regions [2,3,4]. Surgical resection is currently the radical treatment for cHCC-CC, but due to its high invasiveness and poor prognosis, the early postoperative recurrence rates are as high as 57–75% [5]. Since the incidence of cHCC-CC is low and the clinical-imaging features are similar to HCC, there is no staging system for cHCC-CC currently, the prognostic system for cHCC-CC mainly relies on the staging systems of HCC. However, these staging systems were developed for HCC, so they still have many shortcomings for clinical management decisions and prognosis of cHCC-CC [6,7,8].
In the past, numerous models for predicting postoperative recurrence of HCC have been developed based on clinical, pathological, and radiomics characteristics [9,10,11]. However, due to the rarity of cHCC-CC, only a few recurrence prediction models have been specifically developed for this cancer. Previous studies have identified various independent predictors of postoperative recurrence of cHCC-CC, including CA19-9 > 37 U/ml, tumor number, tumor size > 5 cm, microvascular invasion (MVI), peritumoral enhancement in the arterial phase, delayed enhancement, satellite lesions, lymph node metastasis, Mid-kine, and poorly differentiated tumors [12,13,14,15,16,17,18,19]. Although these findings are informative, most of them are from single-center studies, requiring further verifications. Furthermore, early recurrence, which mainly occurs within the initial two years after surgery and has a high recurrence rate of 57–75%, requires particular attention in cHCC-CC management [15,16,17,18, 20, 21]. A recent study developed a model for predicting very early recurrence (i.e., recurrence within 6 months after surgery) of cHCC-CC, However, it lacks preoperative imaging features, which is an important prognostic information [22].
Given the rarity and poor prognosis of cHCC-CC, identifying the risk factors that influence the prognosis of cHCC-CC and predict its recurrence is crucial. This study aims to analyze the relationship between clinical, computed tomography (CT), and pathological features of cHCC-CC and early recurrence by collecting multicenter data from three institutions. In addition, the study aims to establish and validate a scoring model for early recurrence after cHCC-CC surgery to accurately predict individualized early recurrence and guide clinical decision-making.
Materials and methods
Patients
This is a retrospective study in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board (Approve Number: 2023-E423-01) of our hospital that waived the requirement of an informed consent. From January 1, 2012, to December 31, 2020, a retrospective analysis was conducted on 213 cHCC-CC patients confirmed by surgical pathology in three institutions (The 1st affiliated hospital of Guangxi medical University, People’s Hospital of Guangxi Zhuang Autonomous Region and Guangxi Medical University Affiliated Cancer Hospital). The inclusion criteria for patient selection were as follows: (1) presence of a single intrahepatic lesion; (2) confirmation of cHCC-CC through surgical pathology; (3) negative marginal state of resection after radical operation as confirmed under the microscope (R0); (4) high-quality enhanced CT images were obtained within 1 month; and (5) regular follow-up imaging examinations (such as ultrasound, CT, and MRI.) and laboratory examinations within 1 year after operation. The exclusion criteria included: (1) previous treatment for cHCC-CC before operation; (2) adjuvant therapy and extra-hepatic metastasis after operation; (3) loss to follow-up or died of other diseases during the follow-up; and (4) incomplete CT imaging data. (Fig. 1).
After applying inclusion and exclusion criteria, a total of 143 patients were included in the study. Therein, 110 patients from institution 1 (The 1st affiliated hospital of Guangxi medical University) were randomly divided into training set (n = 78) and testing set (n = 32) in the ratio of 7–3. Additionally, a validation cohort was formed (n = 33) from institutions 2 and 3 (People’s Hospital of Guangxi Zhuang Autonomous Region and Guangxi Medical University Affiliated Cancer Hospital).
Follow-up
Early recurrence was defined as the occurrence of a new tumor within a year after radical resection of cHCC-CC. The starting point was the day of the operation, while the endpoint was the detection of intra- and extra-hepatic recurrence within a year post-surgery. All cHCC-CC patients were regularly monitored for 12 months after operation. Within the first six months post-surgery, monthly re-examinations were conducted. Afterward, re-examinations were scheduled every three to 6 months. The routine follow-up protocols include imaging examinations such as CT and MRI and US, and tumor markers such as serum AFP, abnormal prothrombin, AFP-L3, and other tumor markers. If new liver lesions were detected through imaging examinations like ultrasound, CT, MRI or confirmed through puncture or surgical pathological examination, the follow-up ended. The deadline of follow-up was January 31, 2023.
Clinical, pathological data
The clinical data consist of several factors such as age, gender, hepatitis B surface antigen (HBsAg), alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), glutamyl transpeptidase (GGT), Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), albumin (ALB), total protein (TP), prealbumin (PA), total bilirubin (TBIL), direct bilirubin (DBIL), and indirect bilirubin (IBIL). The pathological data were also collected, including MVI, hepatocyte, glypican-3, CD34, CK19, and Ki67.
CT examination
The CT scanners were the GE64 VCT and Siemens Dual Source CT in Institution 1; Siemens Sensation 64CT and Philips iCT256 in Institution 2; and Siemens Sensation 64CT and GE Discovery CT750 in Institution 3. After a plain CT scan, an enhanced scan was performed. A high-pressure syringe was used to inject 1.5 ml/kg of non-ionic contrast agent (300 mgI/ml) at a rate of 3 ml/s through the antecubital vein. The scanning process included the arterial phase (25–30 s), venous phase (55–60 s), and equilibrium period (120 s). The slice thickness was 2 mm, the tube voltage was 120 kV, the tube current was 280 mA, and the rotation speed was 0.5 s per rotation.
Image analysis
The CT images were review independently by two radiologists with ten years of experience, and any discrepancies were resolved through consultation between the two or with a senior doctor who has twenty years of work experience. CT features include: (1) the measurement of the tumor size in the portal phase. (2) Assessing whether the tumor margin was smooth (smooth border) or non-smooth (lobulated or irregularly protruding) as it intrudes into the surrounding normal liver parenchyma. (3) Evaluating whether the tumor has a enhancing capsule, and whether the enhancing capsule was complete (none, complete, or incomplete). The enhancing capsule was defined as uniform and smooth enhancement around the tumor and was evaluated at its evident stage (in the venous phase or equilibrium phase). A complete capsule was defined as continuous coverage of more than 80% of the tumor. (4) The peritumoral enhancement in arterial phase was also determined (none or yes), which was defined as the presence of obvious enhancement in the peritumoral liver parenchyma in the arterial phase and isodensity in the portal venous phase and equilibrium phase. (5) Intratumoral necrosis was identified (none, < 25%, 25%-50%, 51%-75%, > 75%), defined as a low-density area within the tumor without enhancement on enhanced scan. (6) The presence of peritumoral satellite lesions (absent or present) was also recorded, which were defined as cancer lesions that were less than 2 cm from the tumor margin and less than 2 cm in diameter. (7) The dilation of bile duct (none or yes) was examined, defined as low-density conduits accompanying the blood vessels in portal venous phase. (8) Large vein invasion (none or yes) was evaluated, defined as portal vein or hepatic vein filling defect in the venous phase of enhanced scanning. (9) Hepatic porta and para-aortic lymph node enlargement (absent or present) were also noted, defined as lymph node short diameter of 1 cm or more. (10) Finally, the enhancement mode (wash in and wash out, inhomogeneous enhancement, or persistence enhancement) was identified [23].
Statistical analysis
The data were analyzed using SPSS 25.0 and R software (Version 41.0 http://www.Rproject.org). The clinical, CT, and pathological data were compared using the Chi-square and Fisher’s exact tests. Univariate and multivariate logistic regression were used to screen out the features, which were then used to construct the clinical, CT, pathological, clinical-CT, and clinical-CT-pathological combined models. The performance of the models was verified using both the testing and validation sets. The “pROC” package was used to draw the ROC curve and calculate the sensitivity and specificity of each model. The “mda” program package was used to draw the DCA curves to verify the clinical utility of the model. Nomograms and scale curves were drawn using the “rms” package according to the postoperative combined model. The correlation plot of predicted probability versus actual result was drawn using the “ModelGood” package. A statistical significance level of P < 0.05 was used.
Result
Patient characteristics
A total of 143 cHCC-CC patients were included in this study, of which 80 cases (55.9%) experienced relapse within 1 year. Among these, in the training group (n = 78), 42 cases (53.8%) relapsed within 1 year; in the testing group (n = 32), 17 cases (53.1%) experienced relapse within 1 year; and in the validation group (n = 33), 21 cases (63.6%) encountered relapse within 1 year. The clinical, CT, and pathological features of the cHCC-CC patients in the training, testing, and validation groups are presented in Tables 1, 2, and 3, respectively.
Model construction
A total of 33 variables encompasses clinical data, CT features, and pathological data. Through single-factor logistic regression, 10 important variables for early recurrence in cHCC-CC were identified, including AST > 45 U/L (P = 0.0013), ALT > 60 U/L (P = 0.0189), ALP > 125 U/L (P = 0.0111), tumor size > 5 cm (P = 0.0004), tumor margins not smooth (P = 0.0039), intratumoral necrosis (P = 0.0134), continuous enhancement of the tumor margin (P = 0.0168), peritumoral enhancement in the arterial phase (P = 0.0017), large vein invasion (P = 0.0325), and MVI (P = 0.0118). Incorporating these indicators into multivariate logistic regression analysis revealed that AST > 45 U/L, ALP > 125 U/L, and MVI were independent risk factors for early recurrence in cHCC-CC patients. Both univariate and multivariate logistic regression analyses showed that AST had the highest odds ratio for early recurrence of cHCC-CC after radical resection (Table 4).
AST and ALP were used to construct the clinical model of early postoperation recurrence of cHCC-CC. The tumor size, tumor margin, and arterial phase peritumoral enhancement were used to construct the CT model of early recurrence of cHCC-CC. MVI was used as an independent predictor to construct the pathological model. AST, ALP, tumor size, tumor margin, and arterial phase peritumoral enhancement were used to construct the clinic-CT model. MVI was included to construct the clinical-CT-pathological combined models based on the clinic-CT model.
Comparison of predictive performance of different models
The effectiveness of the five models in predicting early recurrence after cHCC-CC resection is presented in Table 5. The results indicate that the combined model outperformed other models in predicting postoperative recurrence, with a higher AUC observed in the training, testing, and validation sets (Fig. 2). Additionally, the combined model demonstrated higher net gain in clinical decision-making (Fig. 3).
Nomogram establishment
The risk prediction model using the nomogram was based on the combined model (Fig. 4). The calibration curve of the nomogram risk model demonstrated that the predicted probability was almost identical to the actual probability in the training, testing and validation sets (Fig. 5). This indicates that the nomogram model’s prediction accuracy is significantly high.
Typical case image
Discussion
Although surgical resection is the main treatment for cHCC-CC, the postoperative recurrence rate remains high, as evidenced by previous studies [5, 15, 17]. More than half of cHCC-CC patients have been shown to experience early recurrence within two years [15,16,17, 20, 21]. Our study found that 55.9% of the 143 patients relapsed within one year, indicating a poor prognosis. To identify patients who are at high risk of recurring, it is not appropriate to use a two-year cut-off point for early recurrence. Therefore, we developed and validated a postoperative comprehensive model that involves preoperative clinical and CT features as well as postoperative pathological risk factors (the features are including AST, ALP, tumor size, tumor margin, arterial phase peritumoral enhancement, and MVI). And then a nomogram was constructed to predict early recurrence (within one year) in cHCC-CC patients who undergo radical surgery. Our study findings demonstrate the effectiveness of the nomogram in predicting early recurrence in such patients. The accuracy rates for the training set, testing set, and validation set were 0.81, 0.78, and 0.82, respectively. This tool can aid clinicians in identifying patients who are at high risk for early recurrence, enabling more robust surveillance strategies and appropriate anti-tumor strategies to be implemented.
CT is a widely used as a noninvasive imaging modality in routine clinical practice for the diagnosis, treatment planning, and monitoring of cancer. The tumor size is considered an essential factor that affects early recurrence following radical resection of cHCC-CC. This may be attributed to the fact that larger tumors exhibit more aggressive invasive biological behavior, grow at a faster rate, and are more prone to infiltrating surrounding liver tissue, penetrating the capsule, and developing intrahepatic metastasis. This finding is consistent with previous studies [13, 15].
Previous research also indicates that irregular tumor margins are significant predictors of liver cancer recurrence [24, 25], with an accuracy of 69.5% reported by Ariizumi et al. [15]. Peritumoral enhancement reflects the blood perfusion of the liver tissue surrounding the tumor. When the tumor thrombus obstructs the small branches of the portal vein around the tumor, there was a decrease in portal vein blood flow and slowed flow velocity in that area [26]. Vascular regulatory factors then regulate the vasodilatation of the branches of the hepatic artery, leading to a compensatory increase in blood flow. This results in abnormal enhancement of the liver tissue around the tumor on CT in the arterial phase. Such enhancement suggests cancer cell infiltration in the blood supply around the tumor, thus increasing the risk of cancer cell dissemination and metastasis. This finding is consistent with the author’s research.
AST and ALP have been recognized as independent risk factors for the early recurrence of cHCC-CC. Previous studies on early recurrence of HCC also highlight the independent influence of AST [27, 28] and ALP [29, 30] as contributing factors. Similarly, MVI has been established as a strong and independent predictor of early postoperative recurrence of cHCC-CC [12, 13, 15, 22], likely because it is associated with the cytokines and proteins secreted by stromal cells in the tumor microenvironment that promote angiogenesis. MVI frequently involves small branches of the portal vein or hepatic vein, which results in early blood vessel dissemination. Tumor cells in these vessels exhibit extensive vascularization, demonstrate rapid growth and have the potential to cause intrahepatic recurrence and distant metastasis [31]. These observations align with the results of the study under discussion.
Wu et al. [22] used MiVI, MaVI, and CA19-9 > 25 u/ml as independent risk factors for very early postoperative recurrence in cHCC-CC patients and constructed a nomogram model, with AUCs of 0.77 (95%CI 0.69–0.85) and 0.76 (95% CI 0.66–0.86) in the training set and validation set, respectively. Compared to that study, our study added CT features (included tumor size, tumor margin and arterial phase peritumoral enhancement) on the basis of clinical, pathological features, and the results improved the predictive power. The AUCs of the model were 0.89 (95% CI 0.81–0.96), 0.85 (95% CI 0.70–0.99) and 0.86 (95% CI 0.72–1.00) in the training, testing, and validation sets, respectively. In addition, our nomogram’s was based on the datasets from three institutions, which was internally and externally validated in testing and validation sets, and the addition of external validation improves model reproducibility and generalization compared to existing models. With this knowledge at their disposal, medical practitioners can now objectively evaluate the various parameters involved in cHCC-CC patients and choose the best treatment strategies and monitoring plans tailored to their patients, ensuring better clinical outcomes.
Our study has several limitations that need to be acknowledged. Firstly, this article is based on a retrospective study, which may lead to bias in the data. Secondly, our study focused on patients who underwent radical hepatectomy, which raises the question of whether our predictive nomogram model can be applied to patients receiving other treatments. Thirdly, near 83% patients in our group infected HBV. We all know that in Eastern countries, the majority of cHCC-CC patients are affected by HBV infection, but it occurs less frequent in western populations, so the generalizability of the conclusion maybe limited.
In conclusion, the nomogram model we constructed using six selected clinicopathologic parameters exhibits exceptional internal and external validity, demonstrating robust predictive power and serving as a valuable clinical decision-making tool with favorable net benefit and calibration.
References
Beaufrère A, Calderaro J, Paradis V (2021) Combined hepatocellular-cholangiocarcinoma: an update. J Hepatol 74(5):1212–1224
Komuta M, Yeh MM (2020) A review on the update of combined hepatocellular cholangiocarcinoma. Semin Liver Dis 40(2):124–130
Zhang G, Chen BW, Yang XB et al (2022) Prognostic analysis of patients with combined hepatocellular-cholangiocarcinoma after radical resection: a retrospective multicenter cohort study. World J Gastroenterol 28(41):5968–5981
Renzulli M, Ramai D, Singh J, Sinha S, Brandi N, Ierardi AM, Albertini E, Sacco R, Facciorusso A, Golfieri R (2021) Locoregional treatments in cholangiocarcinoma and combined hepatocellular cholangiocarcinoma. Cancers (Basel) 13(13):3336
Bahra M, Yahyazadeh A (2023) Surgical strategies for combined hepatocellular-cholangiocarcinoma (cHCC-CC). Cancers (Basel) 15(3):774
Kim DH, Choi SH, Kim DW, Lee SS, Lim YS, Kim SY, Kim HJ, Kim JH, Byun JH (2021) Combined hepatocellular-cholangiocarcinoma: magnetic resonance imaging features and prognosis according to risk factors for hepatocellular carcinoma. J Magn Reson Imaging 53(6):1803–1812
Claasen MPAW, Ivanics T, Beumer BR, de Wilde RF, Polak WG, Sapisochin G, IJzermans JNM (2023) An international multicentre evaluation of treatment strategies for combined hepatocellular-cholangiocarcinoma. JHEP Rep 5(6):100
He C, Mao Y, Wang J et al (2018) The predictive value of staging systems and inflammation scores for patients with combined hepatocellular cholangiocarcinoma after surgical resection: a retrospective study. J Gastrointest Surg 22(7):1239–1250
Ji GW, Zhu FP, Xu Q et al (2020) Radiomic features at contrast-enhanced CT predict recurrence in early stage hepatocellular carcinoma: a multi-institutional study. Radiology 294(3):568–579
Ji GW, Zhu FP, Xu Q et al (2019) Machine-learning analysis of contrast-enhanced CT radiomics predicts recurrence of hepatocellular carcinoma after resection: a multi-institutional study. EBioMedicine 50:156–165
Harding-Theobald E, Louissaint J, Maraj B, Cuaresma E, Townsend W, Mendiratta-Lala M, Singal AG, Su GL, Lok AS, Parikh ND (2021) Systematic review: radiomics for the diagnosis and prognosis of hepatocellular carcinoma. Aliment Pharmacol Ther 54(7):890–901
Jiang XX, Huang XT, Huang CS et al (2020) Long-term outcome and prognostic factors of combined hepatocellular carcinoma and cholangiocarcinoma after curative resection. Gastroenterol Rep (Oxf) 8(2):134–142
Song P, Midorikawa Y, Nakayama H et al (2019) Patients’ prognosis of intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma after resection. Cancer Med 8(13):5862–5871
Zhou C, Wang Y, Ma L et al (2022) Combined hepatocellular carcinoma-cholangiocarcinoma: MRI features correlated with tumor biomarkers and prognosis. Eur Radiol 32(1):78–88
Wang T, Yang X, Tang H et al (2020) Integrated nomograms to predict overall survival and recurrence-free survival in patients with combined hepatocellular cholangiocarcinoma (cHCC) after liver resection. Aging (Albany NY) 12(15):15334–15358
Wang X, Wang W, Ma X et al (2020) Combined hepatocellular-cholangiocarcinoma: Which preoperative clinical data and conventional MRI characteristics have value for the prediction of microvascular invasion and clinical significance? Eur Radiol 30(10):5337–5347
Yamashita YI, Aishima S, Nakao Y et al (2020) Clinicopathological characteristics of combined hepatocellular cholangiocarcinoma from the viewpoint of patient prognosis after hepatic resection: high rate of early recurrence and its predictors. Hepatol Res 50(7):863–870
Ma MC, Chen YJ, Chiu TJ et al (2018) Positive expression of midkine predicts early recurrence and poor prognosis of initially resectable combined hepatocellular cholangiocarcinoma. BMC Cancer 18(1):227
Tian MX, Luo LP, Liu WR et al (2019) Development and validation of a prognostic score predicting recurrence in resected combined hepatocellular cholangiocarcinoma. Cancer Manag Res 5(11):5187–5195
Jeon SK, Joo I, Lee DH et al (2019) Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging. Eur Radiol 29(1):373–382
Ishii T, Ito T, Sumiyoshi S, Ogiso S et al (2020) Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma. World J Surg Oncol 18(1):319
Wu Y, Liu H, Zeng J et al (2022) Development and validation of nomogram to predict very early recurrence of combined hepatocellular-cholangiocarcinoma after hepatic resection: a multi-institutional study. World J Surg Oncol 20(1):60
Huang X, Li Y, Long L (2019) Comparison of imaging and clinically relevant features of combined hepatocellular carcinoma and cholangiocarcinoma with hepatocellular carcinoma. Med Sci Monit 14(25):8595–8601
European Association for the Study of the Liver (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69(1):182–236
Choi SH, Lee SS, Park SH et al (2019) LI-RADS classification and prognosis of primary liver cancers at gadoxetic acid-enhanced MRI. Radiology 290(2):388–397
Renzulli M, Brocchi S, Cucchetti A, Mazzotti F, Mosconi C, Sportoletti C, Brandi G, Pinna AD, Golfieri R (2016) Can current preoperative imaging be used to detect microvascular invasion of hepatocellular carcinoma? Radiology 279(2):432–442
Zang Y, Long P, Wang M et al (2021) Development and validation of prognostic nomograms in patients with hepatocellular carcinoma: a population-based study. Future Oncol 17(36):5053–5066
Wang J, Shan Q, Liu Y et al (2019) 3D MR elastography of hepatocellular carcinomas as a potential biomarker for predicting tumor recurrence. J Magn Reson Imaging 49(3):719–730
Sun P, Chen S, Li Y (2020) The association between pretreatment serum alkaline phosphatase and prognosis in hepatocellular carcinoma: a meta-analysis. Medicine (Baltimore) 99(11):e19438
Shimada S, Mogushi K, Akiyama Y, Furuyama T, Watanabe S, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Kudo A, Arii S, Tanabe M, Wands JR, Tanaka S (2019) Comprehensive molecular and immunological characterization of hepatocellular carcinoma. EBioMedicine 40:457–470
Wang H, Du PC, Wu MC, Cong WM (2018) Postoperative adjuvant transarterial chemoembolization for multinodular hepatocellular carcinoma within the barcelona clinic liver cancer early stage and microvascular invasion. Hepatobiliary Surg Nutr 7(6):418–428
Acknowledgements
We thank those who participated in the study, as well as the radiographers, nurses in the Radiology and Surgery department at the first affiliated hospital Guangxi medical University, People’s Hospital of Guangxi Zhuang Autonomous Region and Guangxi Medical University Affiliated Cancer Hospital in Nanning, China, for their work, support, and enthusiasm for the study. We also express our deep gratitude to Dr Lina Chen, from the CT collaboration of Siemens Healthcare Ltd in Shanghai, China, for her help of the data statistical analysis and the article grammar modification.
Funding
This work was supported by Guangxi Natural Science Foundation Project, Guangxi, China, 2023GXNSFAA026053. National Natural Science Foundation of China, NSFC81360220, 81260214.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by CZ, XG, XH, YW, LC, NL, HL, JL. The first draft of the manuscript was written by CZ and XG, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors have not disclosed any competing interests.
Ethical standard Research involves human participants
All data were from routine clinical test, and there was no clinical intervention for the participants in the study.
Informed consent
All informed consents for the routine clinical tests were obtained from participants. While for the retrospective nature of this study, informed consents for participating in this study were waived by the Institutional Review Board.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Zheng, C., Gu, Xt., Huang, Xl. et al. Nomogram based on clinical and preoperative CT features for predicting the early recurrence of combined hepatocellular-cholangiocarcinoma: a multicenter study. Radiol med 128, 1460–1471 (2023). https://doi.org/10.1007/s11547-023-01726-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11547-023-01726-2